YON E Health raises €250k for its vaginal health device
By News Desk | November 6, 2025
Dutch femtech startup YON E Health has raised €250k in pre-seed funding to develop a smart vaginal health sensor that measures pH and temperature.
The device will monitor key indicators linked to fertility, infection risk and reproductive wellbeing, tackling what the company says are long-standing gaps in women’s healthcare.
Founded by Roswitha Verwer in 2022, the Amsterdam-based startup is creating an at-home medical device for continuous pH and basal body temperature tracking.
pH levels show the acidity of the vaginal environment, with changes often signalling infections or fertility shifts.
Basal body temperature monitoring helps to identify ovulation patterns.
Roswitha Verwer, founder and CEO, said: “When I started YON E, I was told vaginal health was too taboo, too complex, and too ‘niche’ for innovation and investment.
“That’s what motivated and pushed me even more.
“For too long, women have had to guess, self-diagnose, or wait until they show symptoms and something goes wrong with their health.
“We’re changing that, turning silence into data women can actually use.”
The raise follows a surge in investor interest in European femtech this year.
UK-based Hormona secured €7.8m for its hormone-tracking platform, while France’s Solence raised €1.6m for AI-based PCOS digital therapeutics. S
SheMed closed a €43m round for its personalised health platform, and Unfabled has reached around €3m in total funding for its women’s health platform.
Currently, vaginal pH testing relies on single-use paper strips, usually used after symptoms appear.
YON E Health’s sensor aims to allow at-home monitoring of both pH and basal body temperature at once, helping spot early warning signs of imbalance and improve timing for conception.
The round was led by PMK-Group, with support from UniPrisma Venture Studio partners Károly Szántó and Thijmen Meijer, who guided term sheet development.
Matias Toye, founder of Oyster Shield and Dilicheck, provided M&A and fundraising support.
“Vaginal health isn’t a luxury; it’s a foundation of overall wellbeing,” said Dr Muskaan Bhan, chief clinical officer at Yon E Health.
“Our technology bridges the gap between research and reality, empowering women globally with real-time, clinical-grade insights that can prevent complications before they start.”
The company says less than 1 per cent of global medical research funding is directed at conditions specific to women, and only 2.3 per cent of venture capital went to female-founded startups in 2024.
Vaginal pH imbalance can indicate conditions such as bacterial vaginosis (an overgrowth of bacteria), yeast infections, fertility issues and hormonal changes.
YON E Health’s technology is designed to give women and clinicians better visibility into menstrual cycles, microbiome health and fertility windows.
YON E Health has a multidisciplinary team across Amsterdam, Budapest, London, Texas, Boston and Madrid.
The pre-seed funding will support preparations for medical trials – a step towards clinical and consumer launch.